Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ulcer Gastrointestinal Clear all
Completed No phase listed Observational

Quality of Life in Pediatric Inflammatory Bowel Disease

NCT00061737
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 17 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
6
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Sep 27, 2026, 5:03 PM EDT
Completed Phase 4 Interventional Results available

Dose Escalation and Remission (DEAR)

NCT00652145
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine
Drug
Lead sponsor
James Lewis
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
8
States / cities
Naples, Florida • Winter Park, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 27, 2026, 5:03 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease

NCT01810185
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Low dose naltrexone, Placebo
Drug
Lead sponsor
Santa Barbara Cottage Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Sep 27, 2026, 5:03 PM EDT
Completed Phase 4 Interventional Results available

Predicting Response to Standardized Pediatric Colitis Therapy

NCT01536535
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalazine, IV Corticosteroid, Oral Corticosteroids, Additional Therapies, Colectomy
Drug · Other · Procedure
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
4 Years to 17 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Hartford, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 27, 2026, 5:03 PM EDT
Completed Phase 4 Interventional Results available

Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

NCT00693225
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Omeprazole/sodium bicarbonate
Drug
Lead sponsor
Yvonne Romero
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Sep 27, 2026, 5:03 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Specimen and Data Collection for a Novel Biomarker Combination for the Differential Diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome.

NCT07471490
View directory record Official record
Conditions
IBD (Inflammatory Bowel Disease), IBS (Irritable Bowel Syndrome), Gastrointestinal Symptoms
Interventions
Not listed
Lead sponsor
DiaSorin Inc.
Industry
Eligibility
2 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 27, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Oral BT-11 in Ulcerative Colitis

NCT03861143
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BT-11 (440 mg), BT-11 (880 mg), Placebo
Drug
Lead sponsor
NImmune Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Los Angeles, California • Ventura, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 27, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

NCT01204476
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
Interventions
Cixutumumab, Everolimus, Laboratory Biomarker Analysis, Octreotide Acetate, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 27, 2026, 5:03 PM EDT
Completed No phase listed Observational

Data Collection of Patients Treated With the ColonRing™ for the Creation of Circular Compression Anastomosis

NCT01301417
View directory record Official record
Conditions
Diverticulum, Colon, Colorectal Neoplasms, Crohn Disease, Colitis, Ulcerative, Colostomy, Ileostomy - Stoma, Rectal Prolapse, Intestinal Polyposis, Lymphoma, Endometriosis, Intestinal Volvulus
Interventions
ColonRing™
Device
Lead sponsor
novoGI
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Riverdale, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 27, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional

The Influence of a Fasting Mimicking Diet on Ulcerative Colitis

NCT03615690
View directory record Official record
Conditions
Inflammatory Bowel Disease, Diet Modification, Ulcerative Colitis
Interventions
Fasting Mimicking Diet, Regular Diet
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 27, 2026, 5:03 PM EDT
Recruiting Phase 4 Interventional

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

NCT04314375
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Low Dose Budesonide, High Dose Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Garden Grove, California • Indianapolis, Indiana • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 27, 2026, 5:03 PM EDT
Recruiting Phase 3 Interventional

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07185009
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Duvakitug, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years to 80 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
28
States / cities
Tucson, Arizona • Coronado, California • Murrieta, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 27, 2026, 5:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Immune Regulation in Ulcerative Colitis or Crohn s Disease

NCT00001184
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis, Chrohn's Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 27, 2026, 5:03 PM EDT
Terminated Not applicable Interventional Results available

Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed

NCT02235311
View directory record Official record
Conditions
Upper Gastrointestinal Bleed
Interventions
Pantoprazole
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 27, 2026, 5:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dysmenorrhea in Women With Crohn's Disease and Ulcerative Colitis

NCT02274714
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Questionnaire Only
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 27, 2026, 5:03 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

NCT02520284
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Andecaliximab, Placebo
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Dothan, Alabama • Wheat Ridge, Colorado • Lauderdale Lakes, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 27, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

NCT03759041
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Vancomycin Pre-Treatment, Placebo for Vancomycin Pre-Treatment, SER-287, Placebo for SER-287
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
81
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • La Jolla, California + 70 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Sep 27, 2026, 5:03 PM EDT
Completed No phase listed Observational

Exacerbating Factors in Inflammatory Bowel Disease

NCT01405105
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Not listed
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 27, 2026, 5:03 PM EDT
Recruiting Phase 4 Interventional

A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

NCT07654751
View directory record Official record
Conditions
Psoriasis, Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic
Interventions
Breast Milk Sample Collection, Guselkumab
Procedure · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 27, 2026, 5:03 PM EDT
Terminated Phase 2Phase 3 Interventional

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

NCT00279435
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2012 · Synced Sep 27, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

NCT01465763
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
tofacitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Mobile, Alabama • La Jolla, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Sep 27, 2026, 5:03 PM EDT
Not listed Not applicable Interventional

Using Virtual Reality for Patients With Gastrointestinal Disease

NCT03719209
View directory record Official record
Conditions
Gastrointestinal Disease, Inflammatory Bowel Diseases
Interventions
HealthVoyager, Standard Practice
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 25 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 27, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

NCT02958865
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-06651600 or Placebo, PF-06700841 or Placebo, PF-06700841, PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
60
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 27, 2026, 5:03 PM EDT
Not yet recruiting Phase 4 Interventional

Combination CurQD and Vedolizumab in Ulcerative Colitis

NCT07665294
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
CurQD, Placebo, Vedolizumab
Drug
Lead sponsor
Ryan C Ungaro
Other
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 27, 2026, 5:03 PM EDT